Real-World Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer
More than half of patients with metastatic castration-sensitive prostate cancer (mCSPC) did not receiveandrogen deprivation therapy (ADT) plus docetaxel or ADT plus novel hormonal therapies as first-line treatment in 2019, even though these regimens are associated with improved survival compared to ADT alone, according to a study presented at the virtual 2021 ASCO Annual Meeting. These findings were presented by Daniel J. George, MD, FASCO, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, NC. “ADT has served as the standard of care for patients with mCSPC for decades, but recent clinical trials have shown that combining ADT with either docetaxel or novel hormonal therapy leads to improved survival compared to ADT alone,” explained Dr. George during his presentation.